Healthcare company enters into contract with three European medical laboratories for over 30 purchases of autonomous blood sampling equipment
In the rapidly evolving world of medical technology, BHealthCare, a pioneering MedTech company based in Europe, is making waves with its innovative robotic autonomous blood drawing technology, HEIVA.
Established in late 2016, BHealthCare has been at the forefront of autonomous robotic solutions for peripheral vascular access. The company's groundbreaking prototype, HEIVA, was developed in 2020 and has since undergone pilot clinical evaluation.
BHealthCare is among the first in Europe, and one of only a handful of companies worldwide, to offer this advanced robotic technology. The company's commitment to innovation has not gone unnoticed, as it has secured one of its biggest supplier agreements to date and counts European market leaders among its growing list of customers.
HEIVA is currently in the registration process to obtain a CE mark and GCC approval, essential certifications for selling products in the European Economic Area (EEA) and Gulf Cooperation Council countries, respectively. The exact timeline for these approvals is yet to be confirmed, but BHealthCare anticipates obtaining the CE mark next year.
In a significant step forward, BHealthCare has announced supply agreements with three European medical biology laboratories for pre-orders of HEIVA. Once approved, HEIVA will be the first robotic medical technology to autonomously draw blood samples from among thousands of daily patients in selected major European medical laboratory groups.
To support the development and launch of HEIVA, BHealthCare is currently conducting a fundraising round with the aim of completing HEIVA's pivotal clinical trial and launching its industrial manufacturing process. Since its inception, the company has raised 13.5 million EUR (15M USD) in capital funds and grants.
As data becomes increasingly important in adapting to market changes, BHealthCare's achievements underscore the potential for innovative technologies to revolutionise healthcare practices. The company's journey is a testament to the power of innovation and the relentless pursuit of progress in the field of medical technology.
For the most accurate and up-to-date information regarding the current status of CE mark and GCC approval for HEIVA, it would be advisable to contact BHealthCare directly or consult regulatory databases related to medical devices in the EEA and GCC regions.
- BHealthCare's innovative robotic technology, HEIVA, is not only revolutionizing patient care in the field of medical technology but also driving advancements in digital health and health-and-wellness.
- The company's commitment to science and technology is evident as they strive to integrate their groundbreaking autonomous blood drawing technology into mainstream medical-conditions management.
- As BHealthCare navigates the regulatory process for CE mark and GCC approval, their dedication to progress and innovation continues to inspire, promising a brighter future for the healthcare industry.
